Citations

Clear

590 citation(s) found for "Ho, Ben".

131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors
Seropian, Stuart , Foran, James M. , Nath, Rajneesh , Choe, Hannah , Litzow, Mark R. , Koshy, Nebu , Stiff, Patrick J. , Tomlinson, Ben K. , Abhyankar, Sunil , Abedin, Sameem , Al‐Kadhimi, Zaid , Orozco, Johnnie J. , Jamieson, Katarzyna , Schuster, Michael W., Law, Arjun , Mayer, Sebastian , Spross, Jennifer , Li, Kate L, Haeuber, Elaina, Vusirikala, Madhuri , Nahar, Akash, Pagel, John M. , Desai, Avinash, Abboud, Camille N. , Abedin, Sameem , Gyurkocza, Boglarka , Chen, George L. , Kebriaei, Partow , Sabloff, Mitchell , Magalhaes‐Silverman, Margarida , Besien, Koen van , Lazarus, Hillard M. , Sandmaier, Brenda M , Giralt, Sergio , Desai, Avinash

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 2159-2159

10.1182/blood-2023-187433 Get It

Background : Most older patients (pts) with relapsed or refractory (R/R) AML cannot tolerate intensive treatment and are not eligible for curative allogeneic hematopoietic cell transplant (alloHCT). 131I-apamistamab, an anti-CD45 radioimmunoconjugate, delivers high dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells while sparing toxicity to healthy organs. 131I-apamistamab led induction and conditioning can thus provide these pts with access to alloHCT. Methods: The SIERRA trial (NCT02665065) is a multi-center, randomized, controlled Phase 3 study comparing the rate of durable complete remission (dCR) lasting >6 months (mos) after complete remission with/without platelet recovery (CR/CRp) between two groups: 131I-apamistamab led induction and conditioning followed by alloHCT vs physician's choice of conventional care (CC). Pts were randomized (1:1) to CC or 131I-apamistamab with fludarabine and total body irradiation (2 Gy) followed by alloHCT. CR/CRp assessment was 28-56 days post alloHCT or 28-42 days post initiation of therapy on the CC group. Pts in the CC group not achieving leukemia-free state could crossover (CO) to 131I-apamistamab. Here we report the results of a post hoc analysis to determine if the presence of various risk factors (i.e., Karnofsky Performance Status (KPS) <90, HCT Comorbidity Index >3, age >65, adverse-risk cytogenetics, venetoclax failure prior to randomization) influenced achievement of dCR in pts treated with 131I-apamistamab. Results: In total, 153 pts were randomized (CC, n=76; 131I-apamistamab, n=77). All pts who received the therapeutic dose of 131I-apamistamab (n=66) underwent alloHCT vs 14 (18.2%) in the CC group. Of evaluable pts, dCR rates at 6 mos were 22% in the 131I-apamistamab group vs 0% in the CC group (95% CI;12.29, 34.73; p<0.0001). A total of 19 pts (13, 131I-apamistamab group; 6, CO) achieved dCR. Table 1 shows the pt, disease, and transplant characteristics of dCR vs. non-dCR pts. Eight of the 19 pts (42.1%) had primary induction failure and the median time to randomization from diagnosis was 5.4 mos. Approximately 50% of pts (9/19) had adverse-risk cytogenetics. Over 35% (7/19) of the pts had failed prior venetoclax and the median number of prior treatments was 3 (range 1-5). A total of 10/19 (52%) pts had KPS of <90% and a comorbidity index of >3. There was no difference in the rate of dCR when stratifying by number of risk factors for a given pt (0 to 5) with 27% for pts with 0-1 risk factors, 14% for pts with 2-3 risk factors, and 11% for pts with 4-5 risk factors (p=0.251). Conclusion: Pts with R/R AML who have multiple risk factors such as adverse risk cytogenetics, age >65, venetoclax failure, high comorbidity index or poor KPS are typically not considered for alloHCT due to high transplant-related mortality and post-transplant relapse rates. 131I-apamistamab was effective in achieving durable responses in R/R AML pts irrespective of the presence of multiple risk factors and successfully enabled alloHCT in such pts due to its targeted mechanism of action.
A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation
Samaniego, Felipe , Ohanian, Maro , Chandhok, Namrata S. , Sadiq, Ahad A., Mahadevan, Daruka , Cherry, Mohamad , Altman, Jessica K. , Burke, John M. , Koontz, Michael Zach, Villasboas, J. C. C, Tomlinson, Ben K. , Finn, Laura , Melear, Jason M., Priego, Victor, Cobb, Patrick , Cull, Elizabeth H., Conkling, Paul , Cosgrove, David , Tam, Eric , Haney, Donna Nguyen, Hu, Jia, Khan, Nawazish A., Rice, William G. , Bejar, Rafael, Goldberg, Aaron D. , Koller, Paul , Reid, Erin G , Roeker, Lindsey E. , Sinha, Ranjeet Kumar , Khan, Nawazish, Bejar, Rafael

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 5953-5953

10.1182/blood-2023-181151 Get It

INTRODUCTION: Luxeptinib (CG-806; LUX) is an orally active noncovalent kinase inhibitor of Bruton's tyrosine kinase (BTK), wild type and mutant forms of Fms-like tyrosine kinase 3 (FLT3) (including the internal tandem duplicates (ITD), tyrosine kinase domain (TKD), and F691L mutant forms), and growth receptors like KIT, CSF1R, PDGFRα, and TRKs. In prior studies, LUX has been shown to suppress aberrant proliferative signaling in B cell malignancies and acute myeloid leukemia (AML) via regulation of BTK, LYN, SYK, AKT, ERK, and MAPK. LUX is cytotoxic to primary AML cells insensitive to other FLT3 inhibitors and to malignant B-cells insensitive to ibrutinib, at pM and nM concentrations, respectively. AIMS: The primary objectives of these studies are to assess the safety, tolerability, and pharmacokinetics (PK) of LUX and determine recommended phase 2 doses for relapsed or refractory (R/R) AML and B cell malignancy patients. METHODS: In two studies (NCT04477291; NCT03893682), LUX (original formulation, G1) was administered continuously as oral capsules BID in 28-day cycles of ascending cohorts (relapsed or refractory de novo, secondary, or therapy-related AML or higher risk myelodysplastic syndrome (MDS), and relapsed and refractory for B cell lymphoma and chronic lymphocytic/small lymphocytic leukemia). A novel generation 3 (G3) formulation of LUX designed to increase bioavailability was tested at a single-dose (sub-study) for relative bioavailability (RBA), followed by continuous dosing in subsequent R/R AML patients. RESULTS: In the B-cell study (as of 15 th May 2023), LUX has been administered to 36 patients at dose levels from 150 mg to 900 mg BID in patients with a median of 3 lines of prior treatment, with 47.2% having received a BTK-inhibitor. Only one (2.8%) patient had a DLT of hypertension and 14 (38.9%) experienced at least one drug related ≥Grade3 treatment emergent adverse event (TEAE). Two patients (900 mg) are currently on study with no DLT and no ≥Grade 3 related TEAEs. A Follicular lymphoma patient is at cycle 28, and achieved a best response as partial response (PR) with a decrease in lesion size of 76.2%; an SLL patient is at cycle 13, and achieved stable disease (SD) showing a decrease in lesion size of 43.1% (Figure A). The overall best response achieved among the 17 patients who have been on treatment for more than 12 weeks are stable disease (SD) (n=11), partial response (PR) (n=3), minor response (n=2) and complete response (CR) (n=1). As of 5 th June 2023, in the AML trial, a total of 40 patients (16 (40%) FLT3-ITD, 21 (52.5%) FLT3-WT, 2 (5.0%) FLT3-TKD, and 1 (2.5%) unknown mutations) with a median of 3 prior treatments (range, 1 - 10) have been treated with LUX G1 formulation at dose levels from 450 mg - 900 mg BID (n=34) or with 50 mg BID of G3 formulation (n=6). Four (10%) experienced drug related SAE and 7 (17.5%) had a drug related grade ≥3 TEAEs. The most common related TEAEs were lymphocyte count decrease, platelet count decrease, and anemia (n=2; 5% patients each). One (2.5%) patient at 450 mg dose, reported complete remission without minimum residual disease (CRmrd) and remained on study for 56 weeks. In the RBA sub-study, G3 (50 mg) produced comparable exposures to G1 (450-900 mg range) (Figure B) and was, therefore, selected as the starting dose for use in the R/R AML study. Six patients were treated with a continuous dosing of 50 mg BID G3; with plasma levels of 274 ng/mL and 195 ng/mL LUX observed by the end of C1D15 and C1D22 respectively. No drug related Grade ≥3 TEAEs or DLTs were observed in 50 mg BID G3 LUX treated patients; with no new safety signals observed for the G3 formulation. Based on these findings and expected exposures for higher dose levels, the cohort safety review committee has approved escalation of G3 dosing to 200 mg BID at which dosing is ongoing. CONCLUSIONS: LUX has a favorable safety profile in patients at all tested dose levels, for multiple cycles, for both studies. Antitumor activity was observed in a heavily pretreated relapsed AML patient and in multiple B-NHL subtypes and CLL/SLL patients including several with prior ibrutinib exposure. Continuous dosing of patients with R/R AML and Higher-Risk MDS with the G3 formulation is ongoing; with updated clinical data (200 mg dose level) to be presented at the meeting.
Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival
Strouse, Christopher , Oloyede, Temitope, Barba, Pere , Cashen, Amanda F. , Elsawy, Mahmoud , Ganguly, Siddhartha , Geethakumari, Praveen Ramakrishnan , Greenbaum, Uri , Hashmi, Hamza , Kittai, Adam S. , Lulla, Premal , Mead, Elena, Saber, Wael , Pasquini, Marcelo C. , Strouse, Christopher S , Shouval, Roni , Kim, Soyoung , Ahmed, Sairah , Awan, Farrukh T. , Bachanová, Veronika , Badar, Talha , Beitinjaneh, Amer , Dholaria, Bhagirathbhai , Hill, LaQuisa C. , Jain, Michael D. , Jain, Tania , Kebriaei, Partow , Locke, Frederick L. , McGuirk, Joseph P. , Mussetti, Alberto , Nishihori, Taiga , Olson, Amanda L , Pennisi, Martina , Perales, Miguel‐Angel , Riedell, Peter A. , Mirza, Abu‐Sayeef , Magalhaes‐Silverman, Margarida , Shpall, Elizabeth J. , Sorror, Mohamed L. , Wudhikarn, Kitsada , Turtle, Cameron J. , Moskop, Amy

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 355-355

10.1182/blood-2023-181181 Get It

Background: Autologous CAR-T therapy targeting CD19 is an effective treatment for relapsed or refractory large B-cell lymphoma (LBCL). However, morbidity and mortality related to CAR-T toxicity remain significant concerns. This study aims to evaluate the patterns, risk factors, and implications of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19-CAR-T therapy in LBCL. Methods: This retrospective analysis includes 1916 LBCL patients treated with CD19-CAR-T cell therapy (axicabtagene-ciloleucel [axi-cel] 75% and tisagenlecleucel 25%) between 2018 and 2020 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patient demographics, baseline characteristics, treatment-related variables, and clinical outcomes were collected. The incidence, severity and timing of onset of CRS and ICANS (according to median time to onset) were analyzed, factors associated with these outcomes and their impact on overall survival as time dependent covariates were done using Cox Regression multivariate analyses. Results: The median age of the patients was 64 years, with a majority having a Karnofsky performance status (KPS) below 90% (61%) and not receiving bridging therapy (67%). CRS was observed in 75.1% of patients, with 9% experiencing severe CRS (grades ≥ 3). Similarly, 43% of patients experienced ICANS, with 20% having severe ICANS (grade ≥ 3). The median time to toxicity was shorter for CRS (4 days) compared to ICANS (7 days). Nearly all the patients who developed ICANS also experienced CRS (98%; ), and the correlation between these two events and respective severities are shown in the Figure 1a. In the multivariate analyses, factors associated with development of CRS were gender (women, Odds ratio [OR] 1.39, 95% confidence interval [CI] 1.10- 1.76, p=0.006), high LDH at time of infusion (OR 1.56; 95% CI 1.22 - 2.00, p=0.002) and product (axi-cel OR 4.60, 95% CI 3.56 -5.81, p<0.001). Factors associated with the development of ICANS included age (> 65 years, OR 1.83; 1.50-2.24, p<0.001), KPS (<80%, OR 2.48; 1.88-3.27, p<0.001), disease status at infusion (treatment resistant disease, OR 1.98; 1.09-3.58, p=0.024; and untreated relapse OR 2.62, 1.35-5.10, p=0.004) and product (axi-cel, OR 5.85; 4.47-7.64, p<0.0001). Factors associated with severe and early onset CRS and ICANS are listed in the table below. The median follow-up of 14.2 months, the estimated 12-month overall survival, progression-free survival (PFS), and treatment-related mortality were 61.6% (95% CI: 59.4-63.9), 42.2% (39.9-44.5), and 4.3% (3.4-5.3), respectively. Overall CRS, early onset CRS and overall ICANS were not associated with higher mortality, however grade >3 CRS (HR 1.79; 1.41-2.28, p<0.001), grade >3 ICANS (hazard ratio [HR] 1.34; 95% CI 1.13-1.59, p=0.002) and early onset ICANS (<7 days, HR 1.23; 1.05-1.44, p=0.01) were associated with higher mortality. The impact of severe CRS on survival are shown in the landmark analysis at 30 days from infusion in the figure 1B. Conclusion: In the largest analysis of CD19-CAR-T cell therapy toxicities to date, we observed a high burden of CRS and ICANS among LBCL patients. The CAR T cell product type was consistently associated with higher incidence, shorter onset and higher severity of both toxicities. High LDH, older age and low performance score also influence the severity and onset of these outcomes. Additionally, patients who developed higher grades of CRS/ICANS and earlier onset ICANS had a higher mortality, stressing the need to develop novel strategies to mitigate the incidence and optimize management of these patients to improve their outcomes.
Enabling the clinical application of artificial intelligence in genomics: a perspective of the AMIA Genomics and Translational Bioinformatics Workgroup
Walton, Nephi , Nagarajan, Radha, Wang, Chen , Sincan, Murat , Everman, David B. , Walton, Derek C, Alekseyenko, Alexander V. , Song, Qianqian , Uzun, Ece D. Gamsiz , Taylor, Casey Overby , Uzun, Alper , Person, Thomas N., Benos, Panayiotis V , Alekseyenko, Alexander V , Song, Qianqian , Rappoport, Nadav , Zhao, Zhongming , Wang, Chen , Gamsiz Uzun, Ece D , Nagarajan, Radha , Freimuth, Robert R. , McGrath, Scott , Lemas, Dominick J. , Williams, Marc S

Mayo Clinic

Journal of the American Medical Informatics Association | December 1, 2023 | Volume: 31 | Issue: 2 | Pages: 536-541

10.1093/jamia/ocad211 | PMID 38037121 Get It

Abstract Objective Given the importance AI in genomics and its potential impact on human health, the American Medical Informatics Association—Genomics and Translational Biomedical Informatics (GenTBI) Workgroup developed this assessment of factors that can further enable the clinical application of AI in this space. Process A list of relevant factors was developed through GenTBI workgroup discussions in multiple in-person and online meetings, along with review of pertinent publications. This list was then summarized and reviewed to achieve consensus among the group members. Conclusions Substantial informatics research and development are needed to fully realize the clinical potential of such technologies. The development of larger datasets is crucial to emulating the success AI is achieving in other domains. It is important that AI methods do not exacerbate existing socio-economic, racial, and ethnic disparities. Genomic data standards are critical to effectively scale such technologies across institutions. With so much uncertainty, complexity and novelty in genomics and medicine, and with an evolving regulatory environment, the current focus should be on using these technologies in an interface with clinicians that emphasizes the value each brings to clinical decision-making.
Standardizing nomenclature in regional anesthesia: an ASRA-ESRA Delphi consensus study of upper and lower limb nerve blocks
El‐Boghdadly, Kariem , Albrecht, Éric , Wolmarans, Morné , Mariano, Edward R. , Kopp, Sandra L. , Perlas, Anahi , Thottungal, Athmaja , Tulgar, Serkan , Adhikary, Sanjib Das , Barrington, Michael J. , Blanco, Rafael, Boretsky, Karen , Breebaart, Margaretha , Laurent, David Burckett-St , Carvalho, Brendan , Chin, Ki Jinn , Coppens, Steve , Costache, I. , Dam, Mette , Desmet, Matthias , Egeler, C., Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Fox, Ben, Franco, Carlo D. , Gautier, Philippe , Grant, Stuart A. , Grape, Sina , Guheen, Carrie R., Hebbard, Peter , Hernandez, Nadia , Hogg, Rosemary , Holtz, Margaret, Ihnatsenka, Barys , Ilfeld, Brian M. , Kalagara, Hari , Kessler, Paul, Kwofie, Kwesi , Le-Wendling, Linda , Lirk, Philipp , Ludwin, Danielle, Macfarlane, Alan , Μakris, Alexandros , McCartney, Colin J. L. , McDonnell, John G., McLeod, Graeme , Memtsoudis, Stavros G. , Merjavy, Peter , Moran, EML , Nader, Antoun , Neal, Joseph M. , Niazi, Ahtsham U. , Njathi-Ori, Catherine , OʼDonnell, Brian D. , Oldman, Matt, Orebaugh, Steven L. , Parras, Teresa, Pawa, Amit , Peng, Philip , Pulos, Bridget P. , Saporito, Andrea , Sauter, Axel R. , Sebastian, Maria Paz , Sinha, Sanjay K. , Stimpson, James, Tang, Raymond , Tsui, Ban C. H. , Turbitt, Lloyd , Uppal, Vishal , Geffen, Geert J. van, Vermeylen, Kris , Vlassakov, Kamen, Volk, Thomas , Xu, Jeff L. , Elkassabany, Nabil , Kopp, Sandra , Tulgar, Serkan , Adhikary, Sanjib , Altıparmak, Başak , Bloc, Sébastien , Boretsky, Karen , Bowness, James , Carvalho, Brendan , Chin, Ki Jinn , Chuan, Alwin , Costache, Ioana , Dam, Mette , Dhir, Shalini , Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Franco, Carlo D , Grape, Sina , Harbell, Monica W , Hebbard, Peter , Ilfeld, Brian M , Ip, Vivian H Y , Johnson, Rebecca L , Kwofie, M Kwesi , Le-Wendling, Linda , Lobo, Clara , Macfarlane, Alan James Robert , Makris, Alexandros , McLeod, Graeme , Memtsoudis, Stavros G , Moran, E M Louise , Nader, Antoun , Neal, Joseph M , Niazi, Ahtsham U , Orebaugh, Steven L , Pawa, Amit , Peng, Philip , Porter, Steven B , Sala-Blanch, Xavier , Sauter, Axel R , Schwenk, Eric S , Sebastian, Maria Paz , Soffin, Ellen M , Tsui, Ban C H , Turbitt, Lloyd , Uppal, Vishal , van Geffen, Geert J , Vermeylen, Kris , Vlassakov, Kamen , Xu, Jeff L , Elkassabany, Nabil M , Mariano, Edward R , El-Boghdadly, K , Volk, Thomas , Kalagara, Hari , Albrecht, Eric , Coppens, Steve , Wolmarans, Morné , Gadsden, Jeff , Aguirre, José Alejandro , Agur, Anne Maria Reet , Bedforth, Nigel M. , Blanco, Rafael, Chelly, Jacques E. , Chuan, Alwin , Harbell, Monica W. , Ip, Vivian , Johnson, Rebecca L. , Kessler, Paul, Lobo, Clara , Porter, Steven B. , Sala‐Blanch, Xavier , Schwenk, Eric S. , Sidhu, Navdeep S. , Soffin, Ellen M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 22, 2023 | Volume: 49 | Issue: 11 | Pages: 782-792

10.1136/rapm-2023-104884 | PMID 38050174 Get It

Background Inconsistent nomenclature and anatomical descriptions of regional anesthetic techniques hinder scientific communication and engender confusion; this in turn has implications for research, education and clinical implementation of regional anesthesia. Having produced standardized nomenclature for abdominal wall, paraspinal and chest wall regional anesthetic techniques, we aimed to similarly do so for upper and lower limb peripheral nerve blocks. Methods We performed a three-round Delphi international consensus study to generate standardized names and anatomical descriptions of upper and lower limb regional anesthetic techniques. A long list of names and anatomical description of blocks of upper and lower extremities was produced by the members of the steering committee. Subsequently, two rounds of anonymized voting and commenting were followed by a third virtual round table to secure consensus for items that remained outstanding after the first and second rounds. As with previous methodology, strong consensus was defined as ≥75% agreement and weak consensus as 50%–74% agreement. Results A total of 94, 91 and 65 collaborators participated in the first, second and third rounds, respectively. We achieved strong consensus for 38 names and 33 anatomical descriptions, and weak consensus for five anatomical descriptions. We agreed on a template for naming peripheral nerve blocks based on the name of the nerve and the anatomical location of the blockade and identified several areas for future research. Conclusions We achieved consensus on nomenclature and anatomical descriptions of regional anesthetic techniques for upper and lower limb nerve blocks, and recommend using this framework in clinical and academic practice. This should improve research, teaching and learning of regional anesthesia to eventually improve patient care.
Diet’s Impact on Post-Traumatic Brain Injury Depression: Exploring Neurodegeneration, Chronic Blood–Brain Barrier Destruction, and Glutamate Neurotoxicity Mechanisms
Boyko, Matthew , Gruenbaum, Benjamin F. , Merzlikin, Igor , Gruenbaum, Benjamin Fredrick , Boyko, Matthew , Oleshko, Anna, Zlotnik, Alexander Anatolievich

Mayo Clinic

Nutrients | November 4, 2023 | Volume: 15 | Issue: 21 | Pages: 4681

10.3390/nu15214681 | PMID 37960334 Get It

Traumatic brain injury (TBI) has a profound impact on cognitive and mental functioning, leading to lifelong impairment and significantly diminishing the quality of life for affected individuals. A healthy blood–brain barrier (BBB) plays a crucial role in guarding the brain against elevated levels of blood glutamate, making its permeability a vital aspect of glutamate regulation within the brain. Studies have shown the efficacy of reducing excess glutamate in the brain as a treatment for post-TBI depression, anxiety, and aggression. The purpose of this article is to evaluate the involvement of dietary glutamate in the development of depression after TBI. We performed a literature search to examine the effects of diets abundant in glutamate, which are common in Asian populations, when compared to diets low in glutamate, which are prevalent in Europe and America. We specifically explored these effects in the context of chronic BBB damage after TBI, which may initiate neurodegeneration and subsequently have an impact on depression through the mechanism of chronic glutamate neurotoxicity. A glutamate-rich diet leads to increased blood glutamate levels when contrasted with a glutamate-poor diet. Within the context of chronic BBB disruption, elevated blood glutamate levels translate to heightened brain glutamate concentrations, thereby intensifying neurodegeneration due to glutamate neurotoxicity.
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Rabin, Karen R. , Chen, Zhiguo , Ji, Lingyun , Kairalla, John A. , Hitzler, Johann , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Reshmi, Shalini C. , Bhojwani, Deepa , Maloney, Kelly W. , Mattano, Leonard A. , Larsen, Eric , Salzer, Wanda L. , Carroll, William L. , Raetz, Elizabeth A. , Loh, Mignon L. , Angiolillo, Anne , Ji, Lingyun , Hitzler, Johann K , Yang, Jun J.J. , Carroll, Andrew J , Wood, Brent L , Roberts, Kathryn G , Mullighan, Charles G , Harvey, Richard , Willman, Cheryl , Gastier‐Foster, Julie M. , Rheingold, Susan R , Maloney, Kelly W , Mattano, Leonard A , Schore, Reuven J , Burke, Michael J , Winick, Naomi Joan , Raetz, Elizabeth A , Loh, Mignon L , Hunger, Stephen P , Rabin, Karen R , Devidas, Meenakshi , Wood, Brent L. , Roberts, Kathryn G. , Mullighan, Charles G. , Harvey, Richard C. , Chen, I‐Ming , Willman, Cheryl L. , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | October 27, 2023 | Volume: 42 | Issue: 2 | Pages: 218-227

10.1200/jco.23.00389 | PMID 37890117 Get It

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We analyzed data for DS (n = 743) and non-DS (n = 20,067) patients age 1-30 years on four B-ALL standard-risk (SR) and high-risk trials. RESULTS Patients with DS exhibited more frequent minimal residual disease (MRD) ≥0.01% at end induction (30.8% v 21.5%; P < .001). This difference persisted at end consolidation only in National Cancer Institute (NCI) high-risk patients (34.0% v 11.7%; P < .0001). Five-year event-free survival (EFS) and overall survival (OS) were significantly poorer for DS versus non-DS patients overall (EFS, 79.2% ± 1.6% v 87.5% ± 0.3%; P < .0001; OS, 86.8% ± 1.4% v 93.6% ± 0.2%; P < .0001), and within NCI SR and high-risk subgroups. Multivariable Cox regression analysis of the DS cohort for risk factors associated with inferior EFS identified age >10 years, white blood count >50 × 103/μL, and end-induction MRD ≥0.01%, but not cytogenetics or CRLF2 overexpression. Patients with DS demonstrated higher 5-year cumulative incidence of relapse (11.5% ± 1.2% v 9.1% ± 0.2%; P = .0008), death in remission (4.9% ± 0.8% v 1.7% ± 0.1%; P < .0001), and induction death (3.4% v 0.8%; P < .0001). Mucositis, infections, and hyperglycemia were significantly more frequent in all patients with DS, while seizures were more frequent in patients with DS on high-risk trials (4.1% v 1.8%; P = .005). CONCLUSION Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.
Perspectives on Musical Care Throughout the Life Course: Introducing the Musical Care International Network
Spiro, Neta , McConnell, Bonnie B. , Pike, Georgia , Baraldi, Filippo Bonini , Buren, Kathleen Van, Camlin, Dave, Cardoso, Tânya Marques , Çifdalöz, Burçin Uçaner, Dumbauld, Ben, Ettenberger, Mark , Fouché, Sunelle , Frid, Emma , Gosine, Jane, graham-jackson, april l., Grahn, Jessica A. , Harrison, Klisala , Mollison, Sally, Morrison, Steven J. , Pérez-Acosta, Gabriela , Pitt, Jessica , Robledo, Juan-Pablo , Roginsky, Efrat , Shaughnessy, Caitlin , Sunderland, Naomi , Talmage, Alison , Tsiris, Giorgos , Wit, Krista de , Sanfilippo, Katie Rose M. , Mori, Bernd Brabec de , Cross, Ian R.M. , Dumbauld, Ben, Hansen, Kjetil Falkenberg , Ilari, Beatriz Senoi , Perkins, Rosie , Rabinowitch, Tal-Chen

Mayo Clinic

Music & Science | October 20, 2023 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/20592043231200553 Get It

In this paper we report on the inaugural meetings of the Musical Care International Network held online in 2022. The term “musical care” is defined by Spiro and Sanfilippo (2022) as “the role of music—music listening as well as music-making—in supporting any aspect of people's developmental or health needs” (pp. 2–3). Musical care takes varied forms in different cultural contexts and involves people from different disciplines and areas of expertise. Therefore, the Musical Care International Network takes an interdisciplinary and international approach and aims to better reflect the disciplinary, geographic, and cultural diversity relevant to musical care. Forty-two delegates participated in 5 inaugural meetings over 2 days, representing 24 countries and numerous disciplines and areas of practice. Based on the meetings, the aims of this paper are to (1) better understand the diverse practices, applications, contexts, and impacts of musical care around the globe and (2) introduce the Musical Care International Network. Transcriptions of the recordings, alongside notes taken by the hosts, were used to summarise the conversations. The discussions developed ideas in three areas: (a) musical care as context-dependent and social, (b) musical care's position within the broader research and practice context, and (c) debates about the impact of and evidence for musical care. We can conclude that musical care refers to context-dependent and social phenomena. The term musical care was seen as useful in talking across boundaries while not minimizing individual disciplinary and professional expertise. The use of the term was seen to help balance the importance and place of multiple disciplines, with a role to play in the development of a collective identity. This collective identity was seen as important in advocacy and in helping to shape policy. The paper closes with proposed future directions for the network and its emerging mission statement.
The Human Phenotype Ontology in 2024: phenotypes around the world
Gargano, Michael , Matentzoglu, Nicolas , Coleman, Ben , Addo-Lartey, Eunice B, Anagnostopoulos, Anna V. , Anderton, Joel , Avillach, Paul , Bagley, Anita , Bakštein, Eduard , Balhoff, James P. , Baynam, Gareth , Bertram, Holli , Bishop, Somer , Bodenstein, David F. , Botas, Pablo , Cady, J , Cameron, Rhiannon , Castellanos, F , Chan, Lauren , Cruz-Rojo, Jaime , Dahan‐Oliel, Noémi , Davids, Jon R. , Dieuleveult, Maud de , Souza, Vinícius de , Vries, Bert B.A. de , Diaz‐Byrd, Claudia , Duyzend, Michael , Elfeky, Reem , Essaid, Shahim , Fabrizzi, Carolina , Freudenberg‐Hua, Yun , Gabriel, Davera , Moses, Rachel Gore , Green, Ian, Gu, Weihong, Guthrie, Julia, Hamosh, Ada , Hanauer, Marc , Hanušová, Kateřina , He, Yongqun , Helbig, Ingo , Huang, Shangzhi, Joseph, Lisa , Keramatian, Kamyar , King, Bryan , Knoflach, Katrin , Koolen, David A. , Kraus, Megan L , Kroll, Carlo , Kusters, Maaike , Ladewig, Markus S. , Lagorce, David , Laraway, Bryan , Li, Xiarong, Lucano, Caterina , Marazita, Mary L. , Martínez‐Glez, Víctor , McHenry, Toby H, McInnis, Melvin G. , Mihulová, Michaela , Millett, Caitlin E. , Moslerová, Veronika , Narutomi, Kenji, Nevado, Julián , Nierenberg, Andrew A. , Čajbiková, Nikola Novák , Ogishima, Soichi , Olson, Daniel , Ortiz, Abigail, Nanclares, Guiomar Pérez de , Peters, Amy T. , Rapp, Christina , Rath, Ana , Rekerle, Lauren , Roberts, Angharad M. , Roy, Suzy, Sanders, Stephan , Schuetz, Catharina , Schwarz, Martin , Scott, Katie , Seelow, Dominik , Seitz, Berthold , Shen, Yiping , Similuk, Morgan , Simon, Eric S. , Singh, Balwinder , Smith, Cynthia L. , Smolinsky, Jake T , Stafford, Elizabeth , Stefancsik, Ray , Steinhaus, Robin , Strawbridge, Rebecca , Sundaramurthi, Jagadish Chandrabose , Talapova, Polina , Castano, Jair A Tenorio , Tesner, Pavel , Thomas, Rhys H. , Turnovec, Marek , Gijn, Mariëlle van , Vlčková, Markéta , Walden, Anita , Ware, James S. , Wiafe, Addo A, Wiafe, Samuel Agyei , Wiggins, Lisa D. , Williams, Andrew E. , Wu, Chen , Xiong, Hui, Yalın, Nefize , Yamamoto, Yasunori , Yatham, Lakshmi N. , Yocum, Anastasia K. , Young, Allan H. , Yüksel, Zafer , Zandi, Peter P. , Zvolský, Miroslav , Carmody, Leigh , Harris, Nomi L. , Muñoz-Torres, Mónica , Daniš, Daniel , Mungall, Chris , Haendel, Melissa , Robinson, Peter N. , Gargano, Michael A , Bagley, Anita M , Bello, Susan M , Berk, Michael , Bertram, Holli , Bishop, Somer , Blau, Hannah , Bodenstein, David F , Botas, Pablo , Boztug, Kaan , Čady, Jolana , Callahan, Tiffany J , Cameron, Rhiannon , Carbon, Seth J , Castellanos, Francisco , Caufield, J Harry , Chan, Lauren E , Chute, Christopher G , Cruz-Rojo, Jaime , Dahan-Oliel, Noémi , Davids, Jon R , de Dieuleveult, Maud , de Vries, Bert B A , de Vries, Esther , DePaulo, J Raymond , Derfalvi, Beata , Dhombres, Ferdinand , Diaz-Byrd, Claudia , Dingemans, Alexander J M , Donadille, Bruno , Duyzend, Michael , Elfeky, Reem , Essaid, Shahim , Fabrizzi, Carolina , Fico, Giovanna , Firth, Helen V , Freudenberg-Hua, Yun , Fullerton, Janice M , Gilmour, Kimberly , Giordano, Jessica , Goes, Fernando , Moses, Rachel Gore , Griese, Matthias , Groza, Tudor , Guthrie, Julia , Gyori, Benjamin , Hamosh, Ada , Hanauer, Marc , Hanušová, Kateřina , He, Yongqun , Hegde, Harshad , Helbig, Ingo , Holasová, Kateřina , Hoyt, Charles Tapley , Hurwitz, Eric , Jacobsen, Julius O B , Joseph, Lisa , Keramatian, Kamyar , King, Bryan , Knoflach, Katrin , Koolen, David A , Kraus, Megan L , Kusters, Maaike , Ladewig, Markus S , Lagorce, David , Lai, Meng-Chuan , Lapunzina, Pablo , Laraway, Bryan , Lewis-Smith, David , Lucano, Caterina , Majd, Marzieh , Marazita, Mary L , Martinez-Glez, Victor , McInnis, Melvin G , McMurry, Julie A , Mihulová, Michaela , Millett, Caitlin E , Mitchell, Philip B , Moslerová, Veronika , Nematollahi, Shahrzad , Nevado, Julian , Nierenberg, Andrew A , Čajbiková, Nikola Novák , Nurnberger, John I , Ogishima, Soichi , Olson, Daniel , Ortiz, Abigail , Pachajoa, Harry , Perez de Nanclares, Guiomar , Peters, Amy T , Putman, Tim , Rath, Ana , Reese, Justin , Rekerle, Lauren , Sanders, Stephan J , Schuetz, Catharina , Schulte, Eva , Schulze, Thomas , Schwarz, Martin , Scott, Katie , Seelow, Dominik , Seitz, Berthold , Similuk, Morgan N , Simon, Eric S , Singh, Balwinder , Smedley, Damian , Smith, Cynthia L , Smolinsky, Jake T , Sperry, Sarah , Stafford, Elizabeth , Stefancsik, Ray , Steinhaus, Robin , Strawbridge, Rebecca , Sundaramurthi, Jagadish Chandrabose , Talapova, Polina , Tenorio Castano, Jair A , Tesner, Pavel , Thomas, Rhys H , Thurm, Audrey , Turnovec, Marek , van Gijn, Marielle E , Vasilevsky, Nicole A , Vlčková, Markéta , Walden, Anita , Wang, Kai , Wapner, Ron , Ware, James S , Wiafe, Samuel A , Wiggins, Lisa D , Williams, Andrew , Wyrwoll, Margot J , Yalin, Nefize , Yamamoto, Yasunori , Yatham, Lakshmi N , Yocum, Anastasia K , Young, Allan H , Yüksel, Zafer , Zandi, Peter P , Zankl, Andreas , Zarante, Ignacio , Zvolský, Miroslav , Toro, Sabrina , Carmody, Leigh C , Harris, Nomi L , Munoz-Torres, Monica C , Danis, Daniel , Mungall, Christopher J , Köhler, Sebastian , Haendel, Melissa , Robinson, Peter N , Berk, Michael , Chute, Christopher G. , Fico, Giovanna , Fullerton, Janice M. , Giordano, Jessica L. , Jiang, Xiaofeng , Lai, Meng‐Chuan , Schulte, Eva C. , Smedley, Damian , Sperry, Sarah H. , Xiong, Hui

Mayo Clinic

Nucleic Acids Research | October 19, 2023 | Volume: 52 | Issue: D1 | Pages: D1333-D1346

10.1093/nar/gkad1005 | PMID 37953324 Get It

Abstract The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.